Transgenic mouse models of breast cancer

Breast Cancer Research and Treatment

Volumn 39, Issue 1, 1996, Pages 119-135

  Amundadottir, Laufey T ^a,b   Merlino, Glenn ^c   Dickson, Robert B ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast tumorigenesis; Cell cycle genes; Growth factors and receptors; Growth suppressing genes; int genes; Multiple transgenes; Nuclear oncogenes; ras genes; Transgenic mice; Viral oncogenes

Indexed keywords

GROWTH FACTOR; GROWTH FACTOR RECEPTOR; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESEARCH; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE RAS; PRIORITY JOURNAL; TRANSGENE; VIRUS GENE;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; FORECASTING; HUMANS; MICE; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS C-MYC; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0029871172     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806083     Document Type: Article

References (133)

1. Jaenisch R: Transgenic animals. Science 240:1468-1474, 1988
2. Merlino G: Transgenic mice as models for tumorigenesis. Cancer Inv 12:203-213, 1994
3. Frohman MA, Martin GR: Cut, paste and save: New approaches to altering specific genes in mice. Cell 56:145-147, 1989
4. De Larco JE, Todaro GJ: Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 75:4001-4005, 1978
5. Derynck R, Roberts AB, Winkler ME, Chen EY, Goeddel DV: Human transforming growth factor-α: precursor structure and expression in E. coli. Cell 38:287-297, 1984
6. Massague J: Epidermal growth factor-like transforming growth factor. J Biol Chem 258:13614-13620, 1983
7. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS, Berger WH: Synthesis of messenger RNAs for transforming growth factors α and ß; and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712, 1987
8. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Tam JP, Kudlow JE, Lippman ME, Salomon DS: Expression of transforming growth factor a and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2:543-555, 1988
9. Perroteau I, Salomon D, DeBortoli M, Kidwell W, Hazarika P, Pardue R, Dedman J, Tam J: Immunological detection and quantitation of alpha transforming growth factors in human breast carcinoma cells. Breast Cancer Res Treat 7:201-210, 1986
10. Travers MT, Barrett-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powles TJ, Coombes RC: Growth factor expression in normal, benign, and malignant breast tissue. Br Med J 296:1621-1624, 1988
11. Arteaga CL, Hanauske AR, Clark GM, Osborne K, Hazarika P, Pardue RL, Tio F, Von Hoff DD: Immunoreactive α transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res 48:5023-5028, 1988
12. Macias A, Perez R, Hagerstrom T, Skoog L: Identification of transforming growth factor alpha in human primary breast carcinomas. Anticancer Res 7:1271-1280, 1987
13. Normanno N, Qi CF, Gullick WJ, Persico G, Yarden Y, Wen D, Plowman G, Kenney N, Johnson G, Kim N, Brandt R, Martinez-Lacaci I, Dickson RB, Salomon DS: Expression of amphiregulin, cripto-1, and heregulin a in human breast cancer cells. Int J Oncol 2:903-911, 1993
14. LeJeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL: Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 53:3597-3602, 1993
15. Harris AL, Nicholson S: Epidermal growth factor receptors in human breast cancer. In: Lippman ME, Dickson RB (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer, Boston, 1988, pp 93-118
16. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT: TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61: 1137-1146, 1990
17. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC: Overexpression of TGFα in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61: 1121-1135, 1990
18. Matsui Y, Halter SA, Holt JT, Hogan BLM, Coffey RJ: Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice. Cell 61: 1147-1155, 1990
19. Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D, Schlessinger J: The SH2 and SH3 domain containing protein Grb2 links receptor tyrosine kinases to ras signalling. Cell 70:431-442, 1992
20. ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73:611-620, 1993
21. Margolis B, Li N, Koch A, Mohammadi M, Hurwitz DR, Zilberstein A, Ullrich A, Pawson T, Schlessinger J: The tyrosine phosphorylated carboxyterminus of the EGF-receptor is a binding site for GAP and PLC-γ. EMBO J 9:4375-4380, 1990
22. Margolis B, Bellot AM, Honegger AM, Ullrich A, Schlessinger J, Zilberstein A: Tyrosine kinase activity is essential for the association of phospholipase C-γ with the epidermal growth factor receptor. Mol Cell Biol 10:435-441, 1990
23. Hu B, Margolis B, Skolnik EY, Lammers R, Ullrich A, Schlessinger J: Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol 12:981-990, 1992
24. Rozakis-Adcock M, McGlade MJ, Mbamalu G, Pelicci G, Daly RD, Li W, Batzer AG, Thomas S, Brugge J, Pelicci PG, Schlessinger J, Pawson T: Association of the She and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature (London) 360: 689-692, 1992
25. r tumor antigen. Nature 312:513-516, 1984
26. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985
27. Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497-6501, 1985
28. Bargmann CI, Hung M, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986
29. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to the epidermal growth factor receptor. Nature 319:230-234, 1986
30. Bargmann CI, Hung M, Weinberg RA: Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657, 1986
31. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI: A point mutation on the neu oncogene mimics ligand induction of receptor aggregation. Nature 339:230-231, 1989
32. Sternberg MJE, Gullick WJ: Neu receptor dimerization. Nature 339:587, 1989
33. neu stimulates tyrosine kinase phosphorylation in vivo. Mol Cell Biol 8:3969-3973, 1988
34. Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ: Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5:237-239, 1990
35. King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976, 1985
36. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
37. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
38. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243, 1988
39. Tavassoli M, Quirke P, Farzaneh F, Lock NJ, Mayne LV, Kirkham N: c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumor grade, in human breast carcinoma. Br J Cancer 60:505-510, 1989
40. Iglehart D, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50:6701-6707, 1990
41. Gullick WJ: The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer Suppl 5:55-61, 1990
42. Perren TJ: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328-332, 1991
43. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erB2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990
44. Guy C, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89: 10578-10582, 1992
45. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P: Stochastic appearance of mammary tumors on transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931-936, 1989
46. Cardiff RD, Sinn E, Muller W, Leder P: Transgenic oncogenic mice: tumor phenotype predicts genotype. Am J Pathology 139:495-501, 1991
47. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115, 1988
48. Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, Vezzoni P, Clerici L: Early and multifocal tumors in breast, salivary, Harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Letters 64:203-209, 1992
49. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WA: Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14:735-743, 1994
50. Kato GJ, Dang CV: Function of the c-Myc oncoprotein. FASEB J 6:3065-3072, 1992
51. Meichle A, Philipp A, Eilers M: The functions of the Myc proteins. Biochim Biophys Acta 1114:129-146, 1992
52. Landschulz WH, Johnson PF, McKnight SL: The leucine zipper: A hypothetical structure common to a new class of DNA binding proteins. Science 240: 1759-1764, 1988
53. Murre C, McCaw PS, Baltimore D: A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, myoD, and myc proteins. Cell 56:777-783, 1989
54. Prendergast GC, Ziff EB: DNA-binding motif. Nature 341:392, 1989
55. Blackwood EM, Eisenman RN: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211-1217, 1991
56. Cole MD: Myc meets its Max. Cell 65:715-716, 1991
57. Prendergast GC, Lawe D, Ziff EB: Association of Myn, the murine homologue of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation. Cell 65:395-407, 1991
58. Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P: In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665-671, 1988
59. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme M, Gest J, Callahan R: Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83:4834-4838, 1986
60. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alteration of c-myc, c-erbB-2 and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49:6675-6679, 1989
61. Mariani-Costantini R, Escot C, Theillet C, Gentile A, Merlo G, Lidereau R, Callahan R: In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast. Cancer Res 48:199-205, 1988
62. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H: c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51:687-691, 1992
63. Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627-637, 1984
64. Leder A, Pattengale PK, Kuo A, Stewart T, Leder P: Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 45:485-495, 1986
65. Schoenenberger CA, Andres AC, Groner B, van der Valk M, Lemeur M, Gerlinger P: Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J 7:169-175, 1988
66. Edwards PA, Ward JL, Bradbury JM: Alteration of morphogenesis by the v-myc oncogene in transplants of mammary gland. Oncogene 2:407-412, 1988
67. Vonderhaar BK: Regulation of development of the normal mammary gland by hormones and growth factors. In: Lippman ME, Dickson RB (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer Academic Publishers, Norwell MA, 1988, pp 251-266
68. DeOme KB, Faulkin LJ, Bern HA, Blair PB: Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free fat pads of female C3H mice. Cancer Res 19:515-520, 1959
69. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S: Oncogenes and signal transduction. Cell 64:281-302, 1991
70. c-src kinase by middle T or by dephosphorylation. EMBO J 4:1471-1477, 1985
71. Kornbluth S, Sudol M, Hanafusa H: Association of polyomavirus middle-T antigen with c-yes protein. Nature (London) 325:171-173, 1987
72. c-src protein kinase in adult and fetal human tissue: high activity in some sarcomas and mammary carcinomas. Cancer Res 43:1696-1702, 1983
73. c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 262:13754-13759, 1986
74. Ottenhoff-Kalff AE, Rijksen G, van Beurden EACM, Hennipman A, Michels AA, Staal GEJ: Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52:4773-4778, 1992
75. Guy CT, Cardiff RD, Muller WJ: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12:954-961, 1992
76. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ: Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 8:23-32, 1994
77. Levine AJ: The tumor suppressor genes. Ann Rev Biochem 62:623-651, 1993
78. Tzeng Y, Guhl E, Graessmann M, Graessmann A: Breast cancer formation in transgenic animal induced by the whey acidic protein SV40T antigen (WAP-SV-T) hybrid gene. Oncogene 8:1965-1971, 1993
79. Moodie SA, Wolfman A: The 3Rs of life: Ras, Raf and growth regulation. Trends Genet 10:44-48, 1994
80. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA: Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45-51, 1993
81. Hand PH, Thor A, Wunderlich D, Muraro R, Caruso A, Schlom J: Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci USA 81:5227-5231, 1984
82. DeBortoli ME, Abou-Issa H, Haley BE, Cho-Chung YS: Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. Biochem Biophys Res Commun 127: 699-706, 1985
83. Slamon DJ, DeKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 224:256-262, 1984
84. Theillet C, Liderau R, Escot C, Hutzell P, Brunet M, Gest J, Schlom J, Callahan R: Loss of a c-H-ras-1 allele and aggressive human primary breast carcinornas. Cancer Res 46:4776-4781, 1986
85. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49:465-475, 1987
86. Tremblay PJ, Pothier F, Hoang T, Tremblay G, Brownstein S, Liszauer A, Jolicoeur P: Transgenic mice carrying the mouse mammary tumor virus ras fusion gene: distinct effects in various tissues. Mol Cell Biol 9:854-859, 1989
87. Andres A, Schonenberger C, Groner B, Henninghausen L, LeMeur M, Gerlinger P: Ha-ras oncogene expression directed by a milk protein gene promoter: Tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc Natl Acad Sci USA 84:1299-1303, 1987
88. Nusse R: The activation of cellular oncogenes by proviral insertion in murine mammary cancer. In: Lippman ME, Dickson RB (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer Academic Publishers, Norwell MA, 1988, pp 283-306
89. Wilkinson DG, Peters G, Dickson C, McMahon AP: Expression of the FGF-related proto-oncogene int-2 during gastrulation and neurulation in the mouse. EMBO J 7:691-695, 1988
90. Dickson C, Fantl V: Fgf-3, an oncogene in murine breast cancer. In: Lippman ME, Dickson RB (eds) Mammary Tumorigenesis and Malignant Progression. Kluwer Academic Publishers, Norwell MA, 1994, pp 331-344
91. Tsukamoto AS, Grosschedl R, Guman RC, Parslow T, Varmus HE: Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55:619-625, 1988
92. Stamp G, Fantl V, Poulsom R, Jamieson S, Smith R, Peters G, Dickson S: Non-uniform expression of a mouse mammary tumor virus-driven int-2/fgf-3 transgene in pregnancy-responsive breast-tumors. Cell Growth Differ 3:929-938, 1992
93. Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P: The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 9:907-913, 1990
94. Robbins J, Blondel B, Gallahan D, Callahan R: Mouse mammary tumor gene int-3: a member of the notch gene family transforms mammary epithelial cells. J Virol 66:2594-2599, 1992
95. Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G, Callahan R: Expression of an activated notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 6:345-355, 1992
96. Nigro JM, Baker, SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-708, 1989
97. Allred DC, Elledge R, Clark GM, Fuqua SAW: The p53 tumor suppressor gene in human breast cancer. In: Lippman ME, Dickson RB (eds) Mammary Tumorigenesis and Malignant Progression. Kluwer Academic Publishers, Norwell MA, 1994, pp 63-77
98. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
99. Allred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
100. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221, 1992
101. Coles C, Condie A, Chetty U, Steel CM, Evans HJ, Prosser J: p53 mutations in breast cancer. Cancer Res 52:5291-5298, 1992
102. Arg-Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuoalveolar development. Cell Growth Differ 5:711-721, 1994
103. Sporn MB, Roberts AB, Wakefield LM, Crombrugghe B: Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105:1039-1045, 1987
104. Silberstein GB, Daniels CW: Reversible inhibition of mammary gland growth by transforming growth factor-β. Science 237:291-293, 1987
105. Jhappan C, Geiser AG, Kordon EC, Bagheri D, Hennighausen L, Roberts AB, Smith GH, Merlino G: Targeting expression of a transforming growth factor ß1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J 12: 1835-1845, 1993
106. Pierce DF, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, Daniel CW, Hogan BL, Moses HL: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing TGF-beta-1. Genes Dev 7:2308-2317, 1993
107. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T: Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33:389-396, 1983
108. Swenson KI, Farell KM, Ruderman JV: The clam embryo protein cyclin A induces entry into M phase and the resumption of meiosis in Xenopus oocytes. Cell 47:861-870, 1986
109. Standart N, Minshull J, Pines J, Hunt T: Cyclin synthesis, modification and destruction during meiotic maturation of the starfish oocyte. Dev Biol 124:248-258, 1987
110. Draetta G: Cell cycle control in eukaryotes: molecular mechanism of cdc2 activation. Trends Biochem 15:378-383, 1990
111. Tsai L, Harlow E, Meyerson M: Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase. Nature 353: 174-177, 1991
112. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 11:961-971, 1992
113. Hunt T: Cell cycle gets more cyclins. Nature 350: 462-463, 1991
114. Keyomarsi K, Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90:1112-1116, 1993
115. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB: Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54:380-385, 1994
116. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512-515, 1991
117. Matshushime H, Roussel MF, Ashmun RA, Sherr CJ: Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701-713, 1991
118. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL: Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587, 1993
119. Ali IU, Merlo G, Callahan R, Lidereau R: The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. Oncogene 4:89-92, 1989
120. Theillet C, Adane J, Szepetowski P, Simon M, Jeanteur P, Birnbaum D, Gaudray P: BCL-1 participates in the 11q13 amplification found in breast cancer. Oncogene 5:147-149, 1990
121. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DJ, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993
122. Szepetowski P, Ollemdorff V, Grosgeorge J, Courseaux A, Birnbaum D, Theillet D, Gaudray P: DNA amplification at 11q13.5-q14 in human breast cancer. Oncogene 7:2513-2517, 1993
123. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444, 1991
124. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ: Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 7:355-361, 1992
125. Jiang W, Kahn SM, Tomita N, Zhang Y, Lu S, Weinstein IB: Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 52:2980-2983, 1992
126. Wang TC, Cardiff R, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 366: 669-671, 1994
127. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A: Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56:673-682, 1989
128. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A: Identification of cooperating oncogenes in Eu-myc transgenic mice by provirus tagging. Cell 65:737-752, 1991
129. Haupt Y, Alexander WS, Barri G, Klinken LP, Adams JM: Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eu-myc transgenic mice. Cell 65:753-763, 1991
130. Hunter T: Cooperation between oncogenes. Cell 64:249-270, 1991
131. Kwan H, Pecenka V, Tsukamoto A, Parslow TG, Guzman R, Lin T, Muller WJ, Lee FS, Leder P, Varmus HE: Transgenes expressing the wnt-1 and int-1 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice. Mol Cell Biol 12:147-154, 1992
132. Shackleford GM, MacArthur CA, Kwan HC, Varmus HE: Mouse mammary tumor virus infection accelerates mammary carcinogenesis in wnt-1 transgenic mice by insertional activation of int-1/fgf-3 and hst/fgf-4. Proc Natl Acad Sci USA 90:740-744, 1993
133. Amundadottir LT, Johnson MD, Merlino G, Smith G, Dickson RB: Synergistic interaction of TGFα and c-myc in mouse mammary gland tumorigenesis. Cell Growth and Diff 6:737-748, 1995